Winner Medical(SZ:300888) Sou Hu Cai Jing·2026-02-09 12:21Core Viewpoint - The company Steady Medical (300888) has shown significant growth in its financial performance for the first three quarters of 2025, with a notable increase in both revenue and net profit compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a total revenue of 7.897 billion yuan, representing a year-on-year increase of 30.1% [2]. - The net profit attributable to shareholders reached 732 million yuan, up 32.36% year-on-year [2]. - The company's net profit excluding non-recurring items was 679 million yuan, reflecting a 43.93% increase year-on-year [2]. - In the third quarter of 2025 alone, the company achieved a revenue of 2.601 billion yuan, which is a 27.71% increase compared to the same quarter last year [2]. - The net profit for the third quarter was 240 million yuan, marking a 42.11% year-on-year growth [2]. - The net profit excluding non-recurring items for the third quarter was 218 million yuan, showing a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million yuan and financial expenses of -2.036 million yuan [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of February 9, 2026, Steady Medical's stock closed at 35.71 yuan, with a turnover rate of 0.57% and a trading volume of 33,400 hands, resulting in a transaction amount of 119 million yuan [1]. - On February 9, the net outflow of main funds was 8.6952 million yuan, accounting for 7.29% of the total transaction amount, while retail investors saw a net inflow of 15.475 million yuan, representing 12.97% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions have provided ratings for Steady Medical, with 8 giving a "buy" rating and 2 giving a "hold" rating [2]. - The average target price set by institutions over the past 90 days is 5.451 billion yuan [2].